Hereditary Sensory Neuropathy Serine Trial

Summary

This is a randomised double-blind placebo-controlled trial of L-serine in Hereditary Sensory Neuropathy type 1 (HSN1) due to variants in SPTLC1/2 gene. This is a single-centre study being conducted at the National Hospital for Neurology and Neurosurgery, London UK. The SENSE trial will test whether L-serine is an effective drug treatment to slow or stop disease progression in HSN1 due to variants in the SPLTLC1 or SPTLC2 gene. The other aim is to assess if Magnetic Resonance Imaging (MRI) can accurately detect the changes which occur in the muscles of people who have HSN1.

Timeline

Start

2023-08-21

Primary completion

2025-08

Completion

2025-08

Publications

• Kramarz C, Recica L, Morrow J, Skorupinska M, Rossor AM, Laura M, Reilly MM. Health Equality and Socioeconomic Impact of Hereditary Sensory Neuropathy Type 1 (HSN1) in the UK. J Peripher Nerv Syst. 2026 Jun;31(2):e70133. doi: 10.1111/jns.70133.

Drugs

Indications